NovaBridge Biosciences NBP · Stock Open NovaBridge Biosciences in new tab

1.49 USD

Add to portfolio

EPS

-0.48

P/B

0.82

ROE

-40.89

Beta

1.48

Target Price

8.00 USD

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for NovaBridge Biosciences (NBP)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

NovaBridge Biosciences Analysis (NBP)

Official Website Stock

Is NovaBridge Biosciences a good investment? NovaBridge Biosciences (NBP) is currently trading at 1.49 USD. Market analysts have a consensus price target of 8.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: NovaBridge Biosciences is expected to release its next earnings report on June 30, 2026. The market consensus estimate for Forward EPS is -1.06.

Investor FAQ

Does NovaBridge Biosciences pay a dividend?

No, it does not currently pay a dividend.

What asset class is NovaBridge Biosciences?

NovaBridge Biosciences is classified as a Stock.

When is the next earnings date?

The next earnings date is projected to be June 30, 2026. The company currently has a trailing EPS of -0.48.

Company Profile

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

Trades

No dividend information available for this instrument.

Fundamentals

2026 © AllInvestView

Twitter YouTube Reddit Feature Requests Support Pricing Help

Support email: [email protected]

Terms of Service | Privacy Policy

Free Trackers · Dividend Apps · Tax Reporting · UK · Australia · Germany · Guides · Ticker Logos

Stock Directory · Financial Glossary · Portfolio Templates · Top Dividend Stocks · Investing in US · Investing in UK · Import Guides · Stock Comparison · Earnings Recaps

Data disclaimer: AIV (AllInvestView) assumes no liability for the information presented. Users are encouraged to exercise caution and carefully consider the accuracy, completeness, and relevance of the information provided.

It's important to remember that our website should complement your independent market research rather than replace it. The past performance of assets should not be regarded as a guarantee of future results. AllInvestView is not a registered investment advisor or broker/dealer, and the information presented here is for educational and informational purposes only. We value your trust and are committed to providing you with valuable market insights while emphasizing the importance of responsible decision-making in your investment journey.